Abstract
A numerous of molecular targets are involved in neurodegenerative diseases such as Alzheimer disease, Parkinson disease or ALS. Large efforts have been done during the last 10 years, to develop radiopharmaceuticals in order to visualize and to quantify these targets. We will present some radiopharmaceuticals already used in human for research or routine. Moreover, we will present the research on the new tracers such as TAU and synuclein aggregates, new neurotransmission parameters, neuroinflammation. Finally, the role played by these markers for diagnosis, disease evolution and treatment follow-up will be discussed. So the aim of this communication is to present the current situation of molecular imaging research in neurodegenerative diseases exploration, and to discuss the potential applications of the molecular imaging to innovative drug development.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
